REPLIMUNE GROUP, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
REPLIMUNE GROUP, INC. (REPL) had Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued of $0 as of 2022-03-31, per its 10-K filed 2022-05-19.
Discontinued › Balance Sheet › Liabilities
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued · last filed 2022-05-19
- 2022-03-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $0.00.
- 2021-03-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $0.00.
- 2020-03-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $0.00.
- 2019-03-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued |
|---|---|
| 2022-03-31 | $0.00 10-K · filed 2022-05-19 |
| 2021-03-31 | $0.00 10-K · filed 2022-05-19 |
| 2020-03-31 | $0.00 10-K · filed 2021-05-20 |
| 2019-03-31 | $0.00 10-K · filed 2020-06-03 |
| 2018-03-31 | $0.00 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |